This trial will test if luspatercept can reduce the need for blood transfusions in participants with anemia caused by MDS or MDS/MPN. It will also assess the safety and tolerability of luspatercept.
- Myeloproliferative Neoplasms
- Myelodysplastic Syndrome
1 Primary · 4 Secondary · Reporting Duration: End of treatment, up to 18 months
Side Effects for
Awards & Highlights
2 Treatment Groups
Participants with gene mutations other than SF3B1
1 of 2
Participants with SF3B1 mutation
1 of 2
70 Total Participants · 2 Treatment Groups
Primary Treatment: Participants with gene mutations other than SF3B1 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Could you please provide information about the enrollment eligibility for this project?
"Clinicaltrials.gov asserts that this trial, which was initially made public on February 8th 2023, is currently searching for participants with the most recent edit occuring on February 16th 2023." - Anonymous Online Contributor
Does the FDA recognize any additional genetic mutations for this treatment?
"Since there is some data confirming the safety of participants with gene mutations other than SF3B1, but none confirming efficacy, our team assigned it a rating of 2." - Anonymous Online Contributor
To what extent has participation been demonstrated in this clinical experiment?
"Affirmative. According to the information on clinicaltrials.gov, this investigation is actively searching for suitable participants; it was originally posted in February 8th 2023 and last updated a week later. The trial needs 70 recruits from 1 medical centre." - Anonymous Online Contributor